Citigroup Downgrades Nevro to Neutral, Lowers Price Target to $125
Citigroup analyst Joanne Wuensch downgrades Nevro (NYSE:NVRO) from Buy to Neutral and lowers the price target from $198 to $125.
SVB Leerink Maintains Outperform on Nevro, Lowers Price Target to $147
SVB Leerink analyst Danielle Antalffy maintains Nevro (NYSE:NVRO) with a Outperform and lowers the price target from $210 to $147.
Piper Sandler Downgrades Nevro to Neutral, Lowers Price Target to $125
Piper Sandler analyst Adam Maeder downgrades Nevro (NYSE:NVRO) from Overweight to Neutral and lowers the price target from $200 to $125.
William Blair Downgrades Nevro to Market Perform
William Blair analyst Margaret Kaczor downgrades Nevro (NYSE:NVRO) from Outperform to Market Perform.
Nevro Sees Q3 Sales $90M-$93M vs $115.35M Est.
2021 Outlook
Nevro continues to monitor and evaluate the impact the global response to the COVID pandemic has had, and will continue to have, on its operations and financial results. Due to the uncertainties
Nevro Q2 EPS $(0.62) Beats $(0.73) Estimate, Sales $102.33M Miss $102.70M Estimate
Nevro (NYSE:NVRO) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.73) by 15.07 percent. This is a 48.76 percent increase over losses of $(1.21) per share from the same
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
FDA Approves Nevro’s Spinal Cord Stimulation For Diabetic Neuropathy Associated Chronic Pain
The FDA has approved Nevro Corp’s (NYSE:NVRO) Senza system for treating chronic pain associated with painful diabetic neuropathy (PDN). The approval…
Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy
Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced receipt of FDA approval of its Senza® System for